Version history

{
  "session_id": "sess_hypdebate_SDA_2026_04_16_hyp_d_20260426_153245",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n## Expert Assessment: SASP Modulation for Neurodegeneration\n\n### Druggability\n\n**IL-1β**: Highly druggable with established agents—Anakinra (IL-1Ra), Canakinumab (anti-IL-1β antibody). Both FDA-approved for inflammatory conditions. Critical limitation: CNS penetration is poor, requiring significant formulation advances for brain diseases.\n\n**NFKB1/p50**: Transcription factors are traditionally \"undruggable.\" Indirect targeting through IKK complexes (evidence for IKKβ inhibitors) or cofactor disruption (BRG1, HDAC6) represents the viable path, though specificity remains challenging.\n\n**BDNF preservation**: Indirect approaches only—TrkB agonists (BDNF mimetics) exist but none in late-stage neurology trials. This target is more constraint than actionable handle.\n\n### Competitive Landscape\n\n| Approach | Stage | Lead Programs |\n|----------|-------|---------------|\n| **Senolytics** (Dasatinib/Quercetin) | Phase 2 | Mayo Clinic AD trial (NCT04685590); multiple IPF studies |\n| **UBX0101** (Unity Biotech) | Ph2 failed | OA program discontinued, pipeline pivoting |\n| **JAK inhibitors** (Ruxolitinib) | Repurposed | Myelofibrosis; off-label SASP modulation |\n| **Rapamycin/mTOR** | Preclinical | FOXO activation reduces SASP in models |\n\n**SASP modulation sits earlier in the value chain**—theoretically elegant but less industrialized than senolytics.\n\n### Key Practical Concerns\n\n1. **Cell-type specificity remains unsolved**: Distinguishing microglial SASP from astrocyte SASP versus neuronal NF-κB signaling cannot be achieved with current pharmacologic tools.\n\n2. **Timing paradox**: SASP may facilitate early protein clearance; blanket suppression could impair neuroprotective homeostasis.\n\n3. **Pericytes and vasculature**: Emerging evidence (Cell 2024) implicates vascular senescence independently—adding complexity to single-pathway strategies.\n\n### Verdict\n\nModulating rather than eliminating senescent cells is mechanistically appealing and avoids the \"collateral damage\" risks of senolytics. However, translatability hinges on CNS-penetrant IL-1 pathway inhibitors"
}